Arbutus Biopharma loses patent appeal in Europe, Bloomberg reports

The European Patent Office appeals board has revoked one of Arbutus Biopharma’s (ABUS) patents, which is likely to affect its case against Moderna (MRNA) in Switzerland and one Unified Patent Court case, Bloomberg’s Lin Cheng and Avalon Pernell report. European patent EP 2279254 following oppositions filed by affiliates of Moderna and Merck (MRK), according to the report, which adds that Arbutus intends to seek a review by EPO’s Enlarged Board of Appeal. Shares of Arbutus Biopharma are down 16.6% in morning trading.